Company intelligence / Profile preview
JiKang Therapeutics
Shanghai Shi, China
- Ownership
- Private
- Development stage
- Other
01
Overview
JiKang Therapeutics has developed a preclinical nanobody (single-domain antibody) APJ agonist that demonstrates at least 10-fold greater potency than natural apelin and is being advanced toward IND-enabling studies. Preclinical results show enhanced weight-loss efficacy in combination with GLP-1 receptor agonists, improved body composition, and muscle function.
- Therapeutic areas
- EndocrinologyMetabolic Disorders
- Modalities
- Nanobody therapyAntibodyBiologic
- Industry
- Biotech
02
Drug pipeline
1 asset03
Partnerships
BioAge LabsXtalPi
Beyond the preview
Go deeper on JiKang Therapeutics.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on JiKang Therapeutics.